We have also utilized different approaches to reduce the pADPr level in ccRCC cells by stably overexpressing PARG and demonstrated the prominent antitumor effect of this “back-to-normal” intervention. The gene discussed is PARG; the disease is nonpapillary renal cell carcinoma.